Cancer
Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), the Lancet reports
Published in Cancer Weekly, March 31st, 2009
The Phase III study published was led by the American College of Surgeons Oncology Group (ACOSOG) and examined post-surgery, or adjuvant, treatment of more than 700 GIST patients. Researchers found that 98% of patients receiving 400 mg of Gleevec daily remained tumor-free one year after surgery. The study also found Gleevec to be safe and well-tolerated, with a low rate of serious adverse events(1).
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2009-03-31)
More Articles from Cancer Weekly
- Allos Therapeutics, Inc.
Allos Therapeutics’ Pralatrexate Granted Orphan Medicinal Product Designation for the Treatment of Bladder Cancer by the European Commission - Breast Cancer
Sopherion Therapeutics Announces Completion of Enrollment in Phase III Study of Myocet in Metastatic Breast Cancer - Cancer Gene Therapy
Investigators at Sichuan University zero in on cancer gene therapy - Cancer Gene Therapy
Reports on cancer gene therapy findings from Yale University, Medical Department provide new insights - Cancer Gene Therapy
Studies from F. Mori et al in the area of cancer gene therapy described - Cancer Gene Therapy
Studies from F.J. Zhao and co-researchers update current data on cancer gene therapy - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
